HRTX
Heron Therapeutics, Inc. NASDAQ Listed Aug 26, 1987$1.24
Mkt Cap $195.8M
52w Low $0.74
31.6% of range
52w High $2.32
50d MA $0.98
200d MA $1.24
P/E (TTM)
-10.6x
EV/EBITDA
-18.4x
P/B
14.8x
Debt/Equity
9.8x
ROE
-140.9%
P/FCF
-7.8x
RSI (14)
—
ATR (14)
—
Beta
1.42
50d MA
$0.98
200d MA
$1.24
Avg Volume
1.9M
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
4242 Campus Point Court · Cary, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.03 | -0.02 | +33.3% | 1.20 | -0.8% | -0.8% | +0.8% | -4.2% | -1.7% | -9.7% | — |
| Nov 4, 2025 | AMC | -0.01 | -0.05 | -275.3% | 1.14 | -1.8% | -2.6% | -0.9% | +0.0% | +0.9% | +4.5% | — |
| Aug 8, 2025 | AMC | -0.01 | -0.02 | -100.0% | 1.32 | +5.3% | -3.0% | +2.3% | +6.9% | -3.6% | -1.5% | — |
| May 6, 2025 | AMC | -0.01 | 0.01 | +200.0% | 2.42 | -0.8% | -6.6% | -4.0% | -2.8% | -2.8% | -10.2% | — |
| Feb 27, 2025 | AMC | -0.03 | 0.02 | +166.7% | 2.05 | -3.4% | +20.5% | -9.3% | +13.8% | -5.9% | -1.7% | — |
| Nov 12, 2024 | AMC | -0.03 | -0.03 | -9.1% | 1.28 | +2.3% | -5.5% | +2.5% | -4.0% | -1.7% | +1.7% | — |
| Aug 6, 2024 | AMC | -0.04 | -0.06 | -50.0% | 2.67 | -6.4% | -25.1% | +6.5% | -7.0% | +3.5% | -0.5% | — |
| May 7, 2024 | AMC | -0.08 | -0.02 | +75.0% | 2.87 | -1.7% | +4.9% | -2.3% | -5.8% | +1.8% | -0.4% | — |
| Mar 12, 2024 | AMC | -0.15 | -0.07 | +53.3% | 2.36 | +18.6% | +27.5% | +1.3% | +0.3% | -3.3% | -0.3% | — |
| Nov 14, 2023 | AMC | -0.31 | -0.17 | +45.2% | 0.54 | +35.8% | +59.3% | +6.6% | +18.9% | +19.3% | +0.8% | — |
| Aug 14, 2023 | AMC | -0.23 | -0.35 | -52.2% | 1.51 | -7.3% | +10.9% | -2.7% | -0.6% | +1.9% | +4.8% | — |
| May 11, 2023 | AMC | -0.17 | -0.27 | -58.8% | 2.23 | -3.6% | -37.2% | -5.0% | -5.3% | -0.8% | -4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.27 | $1.28 | +0.8% | +9.4% | +7.2% | -0.7% | +0.7% | +0.0% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $1.84 | $1.44 | -21.7% | -28.3% | -3.0% | +2.3% | +6.9% | -3.6% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $1.82 | $1.79 | -1.6% | +4.9% | +1.0% | -0.5% | -4.2% | +0.0% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $2.05 | $1.98 | -3.4% | +20.5% | -9.3% | +13.8% | -5.9% | -1.7% |
| Dec 4 | Needham | Maintains | Buy → Buy | — | $1.18 | $1.98 | +67.8% | +39.0% | +4.9% | -5.8% | +8.0% | +0.6% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $1.28 | $1.31 | +2.3% | -5.5% | +2.5% | -4.0% | -1.7% | +1.7% |
| Sep 25 | Needham | Maintains | Buy → Buy | — | $1.96 | $2.00 | +2.0% | -3.6% | +8.5% | -2.9% | +0.0% | +0.5% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $2.67 | $2.50 | -6.4% | -25.1% | +6.5% | -7.0% | +3.5% | -0.5% |
| May 16 | Needham | Maintains | Buy → Buy | — | $3.00 | $3.00 | +0.0% | +7.3% | -0.6% | +6.2% | +1.2% | +0.9% |
| May 8 | Needham | Maintains | Buy → Buy | — | $2.87 | $2.82 | -1.7% | +4.9% | -2.3% | -5.8% | +1.8% | -0.4% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $2.73 | $2.71 | -0.7% | +7.7% | -1.0% | +1.4% | -0.7% | -5.5% |
| Mar 13 | Needham | Maintains | Buy → Buy | — | $2.36 | $2.80 | +18.6% | +27.5% | +1.3% | +0.3% | -3.3% | -0.3% |
| Nov 15 | Needham | Maintains | Buy → Buy | — | $0.54 | $0.73 | +35.8% | +59.3% | +6.6% | +18.9% | +19.3% | +0.8% |
| Aug 15 | Needham | Maintains | Buy → Buy | — | $1.51 | $1.40 | -7.3% | +10.9% | -2.7% | -0.6% | +1.9% | +4.8% |
| Jul 25 | Needham | Maintains | Buy → Buy | — | $1.54 | $1.57 | +1.9% | -1.9% | +9.3% | -6.7% | +1.3% | +6.4% |
| May 12 | Needham | Maintains | Buy → Buy | — | $2.23 | $2.15 | -3.6% | -37.2% | -5.0% | -5.3% | -0.8% | -4.0% |
| Apr 21 | Needham | Maintains | Buy → Buy | — | $2.55 | $2.55 | +0.0% | +8.2% | -3.6% | -5.3% | +0.0% | +0.4% |
| Mar 24 | Needham | Maintains | Buy → Buy | — | $2.06 | $2.20 | +6.5% | -7.7% | -9.2% | -6.9% | +5.0% | -8.9% |
| Mar 24 | Evercore ISI | Maintains | Outperform → Outperform | — | $2.06 | $2.20 | +6.5% | -7.7% | -9.2% | -6.9% | +5.0% | -8.9% |
| Nov 9 | Needham | Maintains | Buy → Buy | — | $3.45 | $3.30 | -4.3% | -12.8% | +2.3% | +11.7% | -4.9% | -2.1% |
| Jun 30 | Needham | Maintains | Buy → Buy | — | $3.17 | $3.06 | -3.5% | -12.0% | -2.5% | +10.3% | +4.7% | +5.1% |
| May 10 | Needham | Maintains | Buy → Buy | — | $3.61 | $4.06 | +12.5% | -3.0% | -5.7% | +4.2% | +4.4% | -1.4% |
| Dec 2 | SVB Leerink | Maintains | Outperform → Outperform | — | $17.50 | $17.60 | +0.6% | +0.2% | -2.5% | +2.7% | +1.5% | +3.3% |
| May 27 | Guggenheim | Maintains | Buy → Buy | — | $18.44 | $19.50 | +5.7% | +3.0% | -3.1% | -1.1% | +2.7% | -1.4% |
| Mar 2 | Needham | Maintains | Buy → Buy | — | $18.65 | $18.55 | -0.5% | -1.9% | +0.9% | +1.0% | -7.1% | -4.6% |
| Feb 20 | Needham | Maintains | Buy → Buy | — | $21.66 | $21.00 | -3.0% | -2.8% | +1.9% | -2.4% | -8.6% | -3.5% |
| Oct 3 | JMP Securities | Maintains | Market Outperform → Outperform | — | $18.64 | $18.53 | -0.6% | +3.9% | -10.0% | +4.8% | +0.0% | +0.1% |
| Sep 14 | Stifel Nicolaus | Maintains | Buy → Buy | — | $34.48 | $35.05 | +1.7% | +0.5% | -2.5% | +1.2% | -1.5% | -1.8% |
| Jul 19 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $37.75 | $38.30 | +1.5% | +3.3% | +0.0% | +0.0% | -4.1% | -0.1% |
| Jun 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $39.95 | $40.95 | +2.5% | +3.5% | +0.2% | -2.2% | +3.6% | -2.6% |
| Jun 21 | Evercore ISI | Maintains | Outperform → Outperform | — | $30.70 | $39.00 | +27.0% | +30.1% | +3.5% | +0.2% | -2.2% | +3.6% |
| Jan 3 | Leerink Swann | Maintains | Outperform → Outperform | — | $18.50 | $18.75 | +1.4% | +2.2% | -1.9% | +0.0% | -0.7% | +2.0% |
| Oct 31 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.38 | $15.85 | +3.1% | -0.2% | +1.3% | -0.3% | +3.5% | +0.0% |
| Sep 27 | Mizuho | Maintains | Buy → Buy | — | $16.05 | $16.55 | +3.1% | -0.3% | +0.0% | +0.9% | +5.9% | -1.2% |
| Sep 27 | Northland Securities | Maintains | Outperform → Outperform | — | $16.05 | $16.55 | +3.1% | -0.3% | +0.0% | +0.9% | +5.9% | -1.2% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $13.90 | $14.45 | +4.0% | +9.0% | -5.6% | +2.1% | -2.1% | -1.4% |
| Oct 26 | Aegis Capital | Maintains | Buy → Buy | — | $15.90 | $16.20 | +1.9% | -0.9% | -2.5% | -1.3% | -2.0% | +0.0% |
| Oct 3 | Jefferies | Maintains | Buy → Buy | — | $17.23 | $16.46 | -4.5% | -3.6% | -3.1% | +6.9% | -1.0% | -1.2% |
| May 2 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $21.44 | $21.67 | +1.1% | +4.2% | -0.7% | -10.7% | -5.8% | -9.8% |
| Dec 10 | Lake Street | Maintains | Buy → Buy | — | $26.17 | $26.65 | +1.8% | +7.8% | -5.3% | -4.3% | +2.3% | +2.8% |
| Sep 23 | Jefferies | Maintains | Buy → Buy | — | $33.56 | $40.92 | +21.9% | +21.6% | -9.7% | -17.2% | -23.5% | -8.6% |
| Sep 23 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $33.56 | $40.92 | +21.9% | +21.6% | -9.7% | -17.2% | -23.5% | -8.6% |
| Sep 23 | Brean Capital | Maintains | Buy → Buy | — | $33.56 | $40.92 | +21.9% | +21.6% | -9.7% | -17.2% | -23.5% | -8.6% |
| Sep 2 | Bank of America | Maintains | Buy → Buy | — | $35.75 | $37.01 | +3.5% | +3.8% | -2.3% | +3.9% | +10.2% | -6.4% |
| Aug 19 | JMP Securities | Downgrade | Market Outperform → Hold | — | $32.24 | $32.00 | -0.7% | +0.3% | +2.0% | +6.2% | -3.0% | -2.8% |
| Jun 30 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $29.46 | $30.33 | +2.9% | +5.8% | -1.0% | -2.1% | -2.8% | +0.4% |
| Jun 26 | Cowen & Co. | Maintains | Outperform → Outperform | — | $29.39 | $30.09 | +2.4% | +3.0% | -2.7% | +5.8% | -1.0% | -2.1% |
| Jun 19 | Leerink Swann | Maintains | Outperform → Outperform | — | $32.25 | $32.64 | +1.2% | +0.6% | +4.3% | -6.3% | -6.6% | -0.8% |
| Jun 1 | Leerink Swann | Maintains | Outperform → Outperform | — | $19.76 | $21.14 | +7.0% | +23.3% | -4.8% | +14.8% | -1.1% | -0.5% |
| May 29 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.35 | $17.25 | +39.7% | +60.0% | +23.3% | -4.8% | +14.8% | -1.1% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The unexpected executive departure with acceleration of equity vesting likely signals leadership uncertainty at HRTX, potentially pressuring the stock near-term while diluting existing shareholders through accelerated stock awards.
Apr 6
8-K
Unknown — 8-K Filing
Aurinia's executive leadership transition with a new COO appointment signals operational restructuring; the CEO's voluntary compensation waiver suggests confidence in turnaround strategy, potentially reducing near-term cash burn.
Mar 23
8-K
Heron Therapeutics, Inc. -- 8-K Filing
Heron Therapeutics reported strong year-end 2025 financial results and highlighted positive corporate developments, positioning the biotechnology company with momentum entering 2026.
Feb 26
Data updated apr 25, 2026 2:04pm
· Source: massive.com